Trends of obesity management in adults: an analysis across guidelines in China and in Europe

Supplementary material

Supplementary data are available at PCMEDI online.

Conflict of interest

There is no conflicts of interest.

Ethical statement

This study has received approval and authorization for publication from the corresponding author of the Chinese version of the guideline. The Chinese guideline has been approved by the original authors and the journal (Chinese Journal of Endocrinology and Metabolism), and we have received authorization for translation and publication.

References

[1] Chinese Society of Endocrinology Guideline for long-term weight management and clinical practice of anti-obesity medications (2024 Edition). Chinese Journal of Endocrinology and Metabolism 2024;40:545-64. https://doi.org/10.3760/cma.j.cn311282-20240412-00149.

[2] Busetto L, Dicker D, Frühbeck G et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 2024;30:2395-9. https://doi.org/10.1038/s41591-024-03095-3.

[3] Zhang H, Jia Q, Song P et al. Incidence, prevalence, and burden of type 2 diabetes in China: trend and projection from 1990 to 2050. Chin Med J (Engl) 2025;138:1447-55. https://doi.org/10.1097/CM9.0000000000003536

[4] Rubino F, Cummings DE, Eckel RH et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13:22162. https://doi.org/10.1016/S2213-8587(24)00316-4.

[5] Xingchun W, Yueye H, Hang S et al. Clinical characteristics analysis of different obesity phenotypes based on metabolic classification. Chinese Journal of Endocrinology and Metabolism 2015;31:678-83. https://doi.org/10.3760/cma.j.issn.1000-6699.2015.08.006.

[6] Shen Q, Hao L Rethinking obesity classification and individualized diagnosis based on metabolism. Chinese Journal of Endocrinology and Metabolism 2015,31:655-8. https://doi.org/10.3760/cma.j.issn.1000-6699.2015.08.001.

[7] Liu Y, Sheng C, Feng W et al. A multi-center study on glucometabolic response to bariatric surgery for different subtypes of obesity. Front Endocrinol 2022;13:989202. https://doi.org/10.3389/fendo.2022.989202.

[8] Lin Z, Feng W, Liu Y et al. Machine learning to identify metabolic subtypes of obesity: A multi-center study. Front Endocrinol 2021;12:713592. https://doi.org/10.3389/fendo.2021.713592.

[9] Mechanick JI, Hurley DL, Garvey WT Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinol-ogy Position Statement. Endocr Pract 2017;23:372-8. https://doi.org/10.4158/EP161688.PS.

[10] Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. https://doi.org/10.1056/NEJMoa2416394.